Shilpa Medicare has received approval from Central Drugs Standard Control Organisation (CDSCO) -New Delhi to manufacture and market Lenvatinib capsules 4mg and 10mg in India. It is the first company to obtain Generic approval for Lenvatinib Capsules 4mg and 10mg in India.
Lenvatinib capsules 4mg and 10mg is a generic equivalent of reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma. According to IQVIA MAT Q2 2019 data, the Indian market for Lenvatinib capsules 4mg and 10mg is approximately $0.32 million.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1521.95 |
Dr. Reddys Lab | 6279.95 |
Cipla | 1407.55 |
Zydus Lifesciences | 963.50 |
Lupin | 1640.30 |
View more.. |